The Pittsburgh Breast Cancer Consortium
Final rept. 1 Aug 2001 - 31 Jul 2005
PITTSBURGH UNIV PA
Pagination or Media Count:
The University of Pittsburgh Cancer Institute, the Magee-Womens Hospital, the Hematology-Oncology Associates of the UPCI HOA, the Pittsburgh Clinical Research Network, Inc. PCRN, the Magee Womancare Breast Cancer Volunteer Program, and the Pittsburgh Branch of the National Association for the Advancement of Colored People NAACP are collaborating to form the Pittsburgh Breast Cancer Consortium PBCC. The focus of this partnership is the rapid clinical development of new agents for the treatment of metastatic breast cancer MBC. The PBCC will conduct innovative phase I and phase II clinical trials testing new approaches in the treatment of MBC. Accrual to these trials will derive from a consortium of Pittsburgh regional, community based oncology practices of the HOA in collaboration with the Magee-Womens HospitalUniversity of Pittsburgh Cancer Institute Comprehensive Breast Cancer Center CBCC. The specific aims of this proposal are 1 to develop a breast cancer clinical trials infrastructure to allow the rapid phase I and phase II development of novel agents for the treatment of breast cancer with a strong emphasis on community-based practice involvement and 2 to evaluate multiple agents, as well as combinations of agents, using this infrastructure.
- Humanities and History
- Medicine and Medical Research